Chiropractors in Jefferson, GA Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Dr. Matthew E. Pugh, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 33 Hill Top Dr, Jefferson, GA 30549 Phone: 706-387-0390 Fax: 706-387-0137 |
Dr. Todjide Satorey Evans, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 22 S Public Sq, Jefferson, GA 30549 Phone: 770-654-1196 |
 Creative Chiropractic Health Clinic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1872 Washington St, Jefferson, GA 30549 Phone: 706-367-7644 Fax: 706-367-7644 |
Dr. Luis Eduardo Berbessi, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1872 Washington St, Jefferson, GA 30549 Phone: 706-367-7644 Fax: 706-367-7644 |
News Archive
TGA clears Bioline's illumigene Group B Streptococcus test
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform.
Potential fish enzyme biomarker for environmental toxins
The level of the enzyme carbonyl reductase (CBR) is elevated in the livers of fish that have been exposed to cleaned wastewater. Scientists at the University of Gothenburg can show that CBR has properties that may make it suitable to be used as a biomarker, an early warning signal of environmental toxins. The aim of the project is to achieve better environmental monitoring.
Ponatinib ‘superior' to sequential second-generation TKI treatment in CML
Patients with chronic myelogenous leukaemia resistant or intolerant to at least one second-generation tyrosine kinase inhibitor have a higher probability of achieving a response to the third-generation TKI ponatinib than to a further second-generation TKI, research indicates.
Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.
NAHQ offers recommendations to preserve integrity of health care quality and patient safety systems
For too long, progress in preventing medication errors and other mistakes that compromise patient safety in healthcare facilities has been unacceptably slow and patients in the majority of U.S. hospitals may not be much safer today than they were 10 years ago, according to an editorial published in the Journal for Healthcare Quality.
› Verified 1 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists
Chiropractors
Optometrists